Search Results

Check out five New York companies hiring biopharma professionals like you, including 2025 Best Places to Work winners.

Aronora, Inc., a clinical-stage biotech poised to revolutionize blood clot treatment and prevention, today announced it has closed an investment from NYBC Ventures, a venture fund established by New York Blood Center.

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

New York Blood Center Enterprises and Talaris Therapeutics, Inc. announced NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky.

Anteris Technologies Ltd announced a summation of the Company’s presentation at the New York Valves annual Conference held at the Jacob K. Javits Convention Center in New York City.

A new study published online and available in the February print edition of the journal Transfusion shows the mixed reality technology for use during blood donation created by Abbott and Blood Centers of America helps ease donors’ feelings of anxiety and boosts the likelihood they will return to give blood again.

Anteris Technologies Ltd, a structural heart company developing DurAVR™ THV, a new class of TAVR and the world’s only balloon-expandable, single-piece biomimetic aortic replacement valve shaped to mimic the native human valve, announced a summation of the Company’s presentation at the New York Valves annual Conference held at the Jacob K. Javits Convention Center in New York City.

Applied Science, the worldwide leader in whole blood collection products and services, announced that Gulf Coast Regional Blood Center has purchased ASI’s next-generation device, the HemoFlow 500, and HemoVue, its recently introduced cloud-based service that works with HemoFlow devices to provide real-time operational data and analytics that significantly improve blood collection and related processes.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) is pleased to announce a partnership with New York Cancer & Blood Specialists (NYCBS), a group of leading community cancer centers in the United States, to evaluate the Bria-IMT™ combination with a checkpoint inhibitor in its pivotal Phase 3 registration study in advanced breast cancer patients in New York.